secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2025-09-22T23:59:59+00:00
Accession:  0001437749-25-029547
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia gets positive PMDA preliminary consultation on CardiAMP HF trial for Japan approval
--------------------------------------------------------------------------------

- Positive preliminary PMDA consultation on CardiAMP Heart Failure Trial data; formal clinical consultation expected by year-end 2025.
- PMDA requested clarifications on composite endpoints, statistical power, NTproBNP subgroup risk-benefit, Japan target patient count, and US development status.
- BioCardia completing responses to PMDA questions; 178 ischemic HF patients across three trials under review.
- Focus on autologous cell therapy for patients with few therapeutic options, per CEO Peter Altman.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774925029547/0001437749-25-029547-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774925029547/bcda20250919c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-029547

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer